Home > Insider Trading > Filing (0001209191-14-061263)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1505512	Regulus Therapeutics Inc.	RGLS	Pharmaceutical Preparations (2834)	264738379

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1283304	G Kleanthis Xanthopoulos	C/O Regulus Therapeutics Inc. 3545 John Hopkins Court #210 San Diego CA 92121	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-09-30	2,300	$0.38	4,766	No	4	M	Direct
Common Stock	Disposition	2014-09-30	2,300	$7.02	2,466	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2014-09-30	2,300	$0.00	2,300	$0.38

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
452,997		2019-02-08	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	80,216	Indirect	By the Xanthopoulos Family Trust dated September 30, 2011

Footnotes

Includes an aggregate of 2,466 shares of Common Stock acquired by the Reporting Person pursuant to the Issuer's 2012 Employee Stock Purchase Plan: 611 shares were acquired on March 10, 2013; 576 shares were acquired on September 10, 2013; 820 shares were acquired on March 10, 2014 and 459 shares were acquired on September 10, 2014.
Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted August 26, 2013.
The weighted average sale price for the transaction reported was $7.0163, and the range of prices were between $7.00 and $7.09. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.
The shares subject to the option are fully vested.